Enbrel Ankylosing Spondylitis sBLA Clears FDA Cmte.; Modifying Claim Next
Executive Summary
Sponsors seeking a disease-modifying claim for an ankylosing spondylitis indication should assess the radiographic progression of the disease, FDA's Arthritis Advisory Committee agreed during its June 24 review of Amgen/Wyeth's Enbrel
You may also be interested in...
Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added
Amgen/Wyeth is awaiting approval for two additional Enbrel indications following FDA clearance of the TNF-inhibitor for ankylosing spondylitis July 24
Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added
Amgen/Wyeth is awaiting approval for two additional Enbrel indications following FDA clearance of the TNF-inhibitor for ankylosing spondylitis July 24
Ankylosing Spondylitis Guidance To Be Considered By FDA Cmte. In 2004
FDA will convene its Arthritis Advisory Committee to consider a draft guidance on ankylosing spondylitis clinical trial design in the first quarter of 2004